Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2033

Conditions
Nasopharyngeal CarcinomaPD-1Surgery
Interventions
DRUG

Toripalimab

Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.

PROCEDURE

salvage surgery

Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.

Trial Locations (7)

330008

NOT_YET_RECRUITING

The Tenth Affiliated Hospital, Sun Yat-Sen University, Nanchang

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

510080

NOT_YET_RECRUITING

The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou

510515

NOT_YET_RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

510700

NOT_YET_RECRUITING

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou

528000

NOT_YET_RECRUITING

The First People's Hospital of Foshan, Guangzhou

528403

NOT_YET_RECRUITING

Zhongshan People's Hospital, Zhongshan

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

First People's Hospital of Foshan

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Tenth Affiliated Hospital, Sun Yat-sen University

UNKNOWN

lead

Sun Yat-sen University

OTHER

NCT04778956 - Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter